Haleon plc Form 6-K Summary
Business context and reporting period
Haleon plc filed a Form 6-K for March 2024 on March 22, 2024. The filing reports a major-shareholding notification concerning Pfizer Inc., rather than operating or quarterly financial results.
Key financial and ownership metrics
- Pfizer’s resulting voting interest: 22.58%, representing 2,062,236,079 voting rights.
- Prior reported position: 32.00%; Pfizer’s interest therefore decreased by 9.42 percentage points.
- Ordinary shares held: 1,667,778,175, or 18.26% of voting rights.
- Restricted ADSs held: 394,457,904, or 4.32% of voting rights. Each ADS represents two ordinary shares.
- Haleon issued share capital used for the calculation: 9,132,301,104 ordinary shares, following cancellation of shares repurchased from Pfizer.
- The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or operating guidance figures.
Material changes versus the prior comparable disclosure
Pfizer sold 594,000,000 Haleon ordinary shares and 196,554,820 ordinary shares in the form of ADSs pursuant to a global offer. Separately, Haleon repurchased 102,272,727 ordinary shares from Pfizer under a previously approved share purchase deed and subsequently cancelled those shares.
The voting-rights threshold was crossed on March 21, 2024, and Haleon was notified on the same date. Pfizer’s remaining shares are held through BofA Securities, Inc. and Guaranty Nominees Limited on Pfizer’s behalf.
Guidance, outlook, risks, contingencies, and unusual items
The filing contains no management guidance, business outlook, operating risk discussion, or financial contingencies. The principal unusual item is the substantial reduction in Pfizer’s strategic holding through the global offer and Haleon’s related share repurchase.
Facts investors should verify
- Confirm the final settlement and ownership records for Pfizer’s sale and Haleon’s repurchase.
- Verify the 9,132,301,104-share issued-capital base used in calculating Pfizer’s 22.58% interest.
- Assess the potential implications of Pfizer’s reduced strategic ownership for Haleon’s shareholder structure and future share disposals.
- Consult Haleon’s financial results and other filings separately for revenue, profitability, cash flow, leverage, liquidity, and guidance information.